DOCSLIB.ORG

4 Chemogenomics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
4 Chemogenomics 4 Chemogenomics Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Quorum Chemo- Descriptor Spial sensing genomics relationships Conclusions Introduction and perspectives Atomic Pathway Proteome Cellular level level level level Chapter 4: Chemogenomics 4-1 Contents of chapter 4 Contents of chapter 4.................................................................................................. 1 Summary of chapter 4................................................................................................. 2 Introduction ................................................................................................................. 2 Chemogenomic experiments................................................................................... 4 Heterozygous deletions ....................................................................................... 5 Homozygous deletions......................................................................................... 5 Overexpression.................................................................................................... 6 Beyond deletion and overexpression libraries ..................................................... 7 Detection methods................................................................................................... 7 Non-competitive arrays........................................................................................ 7 Competitive mutant pools .................................................................................... 7 Data interpretation and analysis.............................................................................. 8 Clustering............................................................................................................. 8 Matrix operations ................................................................................................. 9 Applications ........................................................................................................... 10 Chemogenomic networks.......................................................................................... 12 Results and discussion.......................................................................................... 13 Interpretation of a chemogenomic network........................................................ 14 Properties of the chemogenomic network.......................................................... 15 Materials and methods .......................................................................................... 16 Data acquisition ................................................................................................. 16 Construction of the chemogenomic network...................................................... 16 Computation of network parameters and overlap with other networks .............. 17 Linking the chemical and biological properties of small molecules ........................... 17 Results and discussion.......................................................................................... 18 What differentiates bioactive small molecules from others? .............................. 18 What differentiates small molecules that hit S. cerevisiae from those that hit Sc. pombe?.............................................................................................................. 20 Conclusions ....................................................................................................... 22 Materials and Methods .......................................................................................... 22 References................................................................................................................ 23 Chapter 4: Chemogenomics 4-2 Summary of chapter 4 A robust knowledge of the interactions between small molecules and specific proteins aids the development of new biotechnological tools, the identification of drug targets, and the gain of specific biological insights. Such knowledge can be obtained through chemogenomic screens. In these screens, each small molecule from a chemical library is applied to each cell type from a library of cells, and the resulting phenotypes are recorded. Chemogenomic screens have recently become very common and will continue to generate large amounts of data. Therefore methods to investigate these data become important. In this chapter, I develop computational methods for the analysis of chemogenomic data. For this, I focus on the fungus Saccharomyces cerevisiae, and, to a lesser extent, Schizosaccharomyces pombe. Parts of this chapter appear in the following articles: Wuster, A. and M. Madan Babu (2008). “Chemogenomics and biotechnology.” Trends Biotechnol 26(5): 252-8. Wuster, A. (2008). “Networking with drugs.” Mol BioSyst 4(1): 14-7 The section on linking the chemical and biological properties of SMs would not have been possible without the help of Laura Schuresko-Kapitzky and Nevan Krogan of the University of California, San Francisco, who generated much of the data this section is based on. Introduction The effects of small molecules (SMs) on cells were central to the research of Paul Ehrlich (1854-1915; figure 4-1). For much of his career he strived to identify 'magic bullets', SMs that would allow him to target specific tissues or microbes whilst sparing others (Ehrlich 1911). In order to find a cure for syphilis, he systematically screened a library of hundreds of SMs for their effect against Treponema pallidum, the causative agent of the disease. After testing 605 different compounds, he eventually identified arsphenamine, which he later marketed as Salvarsan 606 (Gensini, Conti et al. 2007). With this strategy, he initiated a whole new approach to drug discovery which has persisted until today (Lipinski and Hopkins 2004). The aim of Paul Ehrlich's chemical screen was to find an SM that was active against a single pathogen. The data Chapter 4: Chemogenomics 4-3 structure created by his screen was one-dimensional and can be encoded by a single vector of the 606 compounds tested. Nowadays, chemical screens are more complex and wider in scope. In this chapter, I mostly work with the data obtained through two- dimensional chemogenomic screens. As in Paul Ehrlich's screen, the first dimension in such screens is a chemical library. The second dimension is a library of different cell types. For the data I work with in this chapter, the cell types are well-defined mutants in a library of S. cerevisiae deletion strains, where in each strain a different gene has been deleted. Alternatively, the cell types could be defined in other ways, such as in a library of cancer cell lines or of meiotic recombinants (Perlstein, Deeds et al. 2007; Perlstein, Ruderfer et al. 2007). The resulting data structure is a two- dimensional matrix where each data point has two coordinates and one specific associated value. The chemical coordinate specifies the SM that was applied, whilst the genetic coordinate specifies the cell type. The value of each data point is a measurement of the phenotype of interest, such as viability, growth rate, or cell size and shape. The results of a large number of chemogenomic screens with different designs have been published (table 4-B). They all have in common the data structure described above, but the experimental designs and aims, such as the identification of cellular targets of SMs, or the characterisation of cellular pathways, vary between them. In this chapter, I describe the different ways in which chemogenomic data can be created, and then introduce the methods that I have developed to extract information from this data. For this purpose, I have divided the results of this chapter into two parts. The first part, on chemogenomic networks, takes a gene-centric view, whilst the second part, on linking the chemical and biological properties of SMs, takes an SM-centric view. I have only tested the methods in this chapter on S. cerevisiae, and, to a lesser extent, on Sc. pombe. Nevertheless, they can potentially also be applied to other systems, such as humans. Figure 4-1. Paul Ehrlich (1854-1915) on a former D-Mark banknote. The molecular structure to the left of the portrait symbolises arsphenamine. The six-membered ring in the centre consists of arsenic atoms. It was not shown until 16 years after the issue of the banknote that arsphenamine is actually a mixture of compounds with three- and five-membered arsenic rings (Lloyd, Morgan et al. 2005). Source of the image: http://tinyurl.com/l3r9np Chapter 4: Chemogenomics 4-4 Chemogenomic experiments An in-depth understanding of the subtly different ways in which chemogenomic experiments are designed is necessary in order to develop the appropriate methods to extract meaningful information from them. Although for all methods of carrying out chemogenomic screens the resulting data structure is similar, its interpretation depends on the design of the experiment. For yeast, there are at least three different types of mutant libraries that can be generated, such as heterozygous deletions, homozygous deletions, and overexpression libraries (table 4-1). Screen A. Homozygous deletants B. Heterozygous C. Overexpression design → deletants ↓ Detection Non- competitive (Baetz, McHardy et al. 2004) arrays 1 SM > 5000 mutants aim: determine mode of action (Luesch, Wu et al. 2005) (Dudley, Janse et al. 2005) for drugs 1’000 SMs 21 conditions 7’296 mutants 4’710 mutants (Chang, Bellaoui et al. 2002) aim: identify protein targets for aim: determine gene function
Load more

Recommended publications
  • Chemical Genomics 33
    Curr. Issues Mol. Biol. (2002) 4: 33-43. Chemical Genomics 33 Chemical Genomics: A Systematic Approach in Biological Research and Drug Discovery X.F. Steven Zheng1* and Ting-Fung Chan2 synthesis (Russell and Eggleston 2000) and new screening technologies such as small chemical compound (MacBeath 1Department of Pathology and Immunology and 2Molecular et al. 1999) and protein microarrays (MacBeath and and Cellular Biology Program, Campus Box 8069 Schreiber 2000; Zhu et al. 2000; Haab et al. 2001). In this Washington University School of Medicine article, we will provide a detailed analysis of the current 660 South Euclid Avenue, St. Louis, Missouri 63110 USA state of chemical genomics and its potential impact on biological and medical research, and pharmaceutical development. Abstract Chemical Biology or Genetics The knowledge of complete sequences of different organisms is dramatically changing the landscape of Since the seminal study of pea genetics by Mendal in 1865, biological research and pharmaceutical development. genetic analysis has been the benchmark for understanding We are experiencing a transition from a trial-and-error gene or protein functions. In classical genetics or forward approach in traditional biological research and natural genetics, the genomic DNA of a model organism or cell is product drug discovery to a systematic operation in randomly mutagenized to generate large numbers of genomics and target-specific drug design and mutants, which are screened for a desirable phenotype or selection. Small, cell-permeable and target-specific trait, such as alteration in growth, appearance or behavior. chemical ligands are particularly useful in systematic The phenotypes are then used to identify the responsible genomic approaches to study biological questions.
    [Show full text]
  • Molecular Design. Concepts and Applications Gisbert Schneider & Karl-Heinz Baringhaus DOI: 10.3395/Reciis.V3i2.259En
    [www.reciis.cict.fiocruz.br] ISSN 1981-6286 Book Reviews Molecular design. Concepts and applications Gisbert Schneider & Karl-Heinz Baringhaus DOI: 10.3395/reciis.v3i2.259en Carlos Alberto Manssour Fraga Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil [email protected] This book focuses on how different concepts and molecular modeling strategies could be exploited to design the molecular architecture of ligands for specific targets, as new drug candidates. The authors have large experience in drug discovery, occupying head positions in European pharmaceutical industries, which was crucial to their particular form to address the main design-related medicinal chemistry topics along the five chapters of the book. The foreword written by Hugo Kubinyi describes the importance of integrated and multidisciplinary work for the successful of rational drug design process. So, Schneider and Baringhaus used an easy and clear lan- guage to show the main advantages and disadvantages of several different approaches and technologies applied in molecular design of new chemical entities, highlighting the pitfalls and risks of the complex task of discovery a new drug. The first chapter presents the principal structural elements related to the molecules and what features should be persecuted to avoid or minimize the probability of unsuccessful during the clinical trials due to inadequate ADMET properties. In addition to the description of druglikeness properties, an important discussion about the importance of getting informations about the shape and the bioactive conformation of the Wiley-VCH Verlag GmbH, bioligands is included. The second one introduces the Alemanha; 2008 phenomena related to receptor-ligand interactions point- ing the more frequent types of bonds involved in the binding and how the enthalpic and entropic contribu- ISBN: 978-3527314324 tions could benefit the formation of stable complexes.
    [Show full text]
  • Download Download
    MM Matin et al. Medical Research Archives vol 8 issue 7. Medical Research Archives RESEARCH ARTICLE 2e`1 PASS Predication, Antiviral, in vitro Antimicrobial, and ADMET Studies of Rhamnopyranoside Esters Authors Mohammed M Matin1, Mohammad HO Roshid2, Sreebash C Bhattacharjee3 and Abul KMS Azad4 Affiliations 1 Bioorganic & Medicinal Chemistry Laboratory, Department of Chemistry, University of Chittagong, Chattogram-4331, Bangladesh 2 Department of Anaesthesia and Intensive Care Medicine, Chattogram Medical College, Chattogram- 4203, Bangladesh 3 Chemical Research Division, Bangladesh Council of Scientific & Industrial Research (BCSIR) Laboratories, Chattogram-4220, Bangladesh 4 Department of Chemistry, Chattogram Govt. College, Chattogram-4203, Bangladesh Corresponding Author: MM Matin E-mail address: [email protected] Tel.: +88 01716 839689. Abstract Sugar derived esters (SEs) with potential antimicrobial activity were found to be a better choice to solve the multidrug resistant (MDR) pathogens due to improved antimicrobial efficacy, biodegradability, non-toxic, and non-allergic properties. In this context, a series of benzyl -L- rhamnopyranoside esters with different chain length (C2-C18) were employed for PASS predication, antiviral, and in vitro antimicrobial activity test. The in vitro antimicrobial tests against four bacterial, and four fungal pathogens along with PASS predication indicated that these sugar esters acted as better antifungals as compared to antibacterial functionality. The study revealed that the incorporation of octanoyl (C8) and lauroyl (C12) group(s) at C-3 position of rhamnopyranoside possessed promising antimicrobial, and anti-carcinogenic potentiality with good pharmacokinetic (pkCSM), and drug likeness properties. Also, attachment of multiple ester groups enhanced various drug likeness, and medicinal chemistry friendliness conditions. Overall, the present findings might be useful for the development of rhamnopyranoside based novel MDR antimicrobial drugs.
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Fast Three Dimensional Pharmacophore Virtual Screening of New Potent Non-Steroid Aromatase Inhibitors
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE J. Med. Chem. 2009, 52, 143–150 143 provided by Estudo Geral Fast Three Dimensional Pharmacophore Virtual Screening of New Potent Non-Steroid Aromatase Inhibitors Marco A. C. Neves,† Teresa C. P. Dinis,‡ Giorgio Colombo,*,§ and M. Luisa Sa´ e Melo*,† Centro de Estudos Farmaceˆuticos, Laborato´rio de Quı´mica Farmaceˆutica, Faculdade de Farma´cia, UniVersidade de Coimbra, 3000-295, Coimbra, Portugal, Centro de Neurocieˆncias, Laborato´rio de Bioquı´mica, Faculdade de Farma´cia, UniVersidade de Coimbra, 3000-295, Coimbra, Portugal, and Istituto di Chimica del Riconoscimento Molecolare, CNR, 20131, Milano, Italy ReceiVed July 28, 2008 Suppression of estrogen biosynthesis by aromatase inhibition is an effective approach for the treatment of hormone sensitive breast cancer. Third generation non-steroid aromatase inhibitors have shown important benefits in recent clinical trials with postmenopausal women. In this study we have developed a new ligand- based strategy combining important pharmacophoric and structural features according to the postulated aromatase binding mode, useful for the virtual screening of new potent non-steroid inhibitors. A small subset of promising drug candidates was identified from the large NCI database, and their antiaromatase activity was assessed on an in vitro biochemical assay with aromatase extracted from human term placenta. New potent aromatase inhibitors were discovered to be active in the low nanomolar range, and a common binding mode was proposed. These results confirm the potential of our methodology for a fast in silico high-throughput screening of potent non-steroid aromatase inhibitors. Introduction built and proved to be valuable in understanding the binding 14-16 Aromatase, a member of the cytochrome P450 superfamily determinants of several classes of inhibitors.
    [Show full text]
  • Link Mining for Kernel-Based Compound-Protein Interaction Predictions Using a Chemogenomics Approach
    Link Mining for Kernel-based Compound-Protein Interaction Predictions Using a Chemogenomics Approach Masahito Ohue1,2,3,4*, Takuro Yamazaki3, Tomohiro Ban4, and Yutaka Akiyama1,2,3,4* 1Department of Computer Science, School of Computing, Tokyo Institute of Technology, Japan 2Advanced Computational Drug Discovery Unit, Institute of Innovative Research, Tokyo Institute of Technology, Japan 3Department of Computer Science, Faculty of Engineering, Tokyo Institute of Technology, Japan 4Department of Computer Science, Graduate School of Information Science and Engineering, Tokyo Institute of Technology, Japan *[email protected], [email protected] Abstract. Virtual screening (VS) is widely used during computational drug dis- covery to reduce costs. Chemogenomics-based virtual screening (CGBVS) can be used to predict new compound-protein interactions (CPIs) from known CPI network data using several methods, including machine learning and data min- ing. Although CGBVS facilitates highly efficient and accurate CPI prediction, it has poor performance for prediction of new compounds for which CPIs are un- known. The pairwise kernel method (PKM) is a state-of-the-art CGBVS method and shows high accuracy for prediction of new compounds. In this study, on the basis of link mining, we improved the PKM by combining link indicator kernel (LIK) and chemical similarity and evaluated the accuracy of these methods. The proposed method obtained an average area under the precision-recall curve (AUPR) value of 0.562, which was higher than that achieved by the conven- tional Gaussian interaction profile (GIP) method (0.425), and the calculation time was only increased by a few percent. Keywords: virtual screening; compound-protein interactions (CPIs); pairwise kernel; link mining; link indicator kernels (LIKs) 1 Introduction Virtual screening (VS), in which drug candidate compounds are selected by a computational method, is one of the main processes in the early stages of drug dis- covery.
    [Show full text]
  • Endogenous Metabolites in Drug Discovery: from Plants to Humans
    Endogenous Metabolites in Drug Discovery: from Plants to Humans Joaquim Olivés Farrés TESI DOCTORAL UPF / ANY 201 6 DIRECTOR DE LA TESI: Dr. Jordi Mestres CEXS Department The research in this T hesis has been carried out at the Systems Pharmacolo gy Group , within the Research Programme on Biomedical Informatics (GRIB) at the Parc de Recerca Biomèdica de Barcelona (PRBB). The research presented in this T hesis has been supported by Ministerio de Ciencia e Innovación project BIO2014 - 54404 - R and BIO2011 - 26669 . Printing funded by the Fundació IMIM’s program “Convocatòria d'ajuts 2016 per a la finalització de tesis doctorals de la Fundació IMIM.” Agraïments Voldria donar les gràcies a tanta gent que em fa por deixar - me ningú. Però per c omençar haig agrair en especial al meu director la tesi, Jordi Mestres, per donar - me la oportunitat de formar part del seu laboratori i poder desenvolupar aquí el treball que aquí es presenta. A més d’oferir l’ajuda necessària sempre que ha calgut. També haig de donar les gràcies a tots els companys del grup de Farmacologia de Sistemes que he anat coneguent durants tots aquests anys en què he estat aquí, en especial en Xavi, a qui li he preguntat mil coses, en Nikita, pels sdfs que m’ha anat llençant a CTL ink, i la Irene i la Cristina, que els seus treballs també m’ajuden a completar la tesis. I cal agrair també a la resta de companys del laboratori, l’Albert, la Viktoria, la Mari Carmen, l’Andreas, en George, l’Eric i l’Andreu; de Chemotargets, en Ricard i en David; i altres membres del GRIB, com són l’Alfons, en Miguel, en Pau, l’Oriol i la Carina.
    [Show full text]
  • Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
    REVIEW published: 03 July 2018 doi: 10.3389/fmicb.2018.01367 Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis Diana Machado 1, Miriam Girardini 2, Miguel Viveiros 1* and Marco Pieroni 2* 1 Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisbon, Portugal, 2 P4T Group, Department of Food and Drug, University of Parma, Parma, Italy The emergence of multi- and extensively drug resistant tuberculosis worldwide poses a great threat to human health and highlight the need to discover and develop new, effective and inexpensive antituberculosis agents. High-throughput screening assays Edited by: against well-validated drug targets and structure based drug design have been employed Fernando Rogerio Pavan, to discover new lead compounds. However, the great majority fail to demonstrate any Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Brazil antimycobacterial activity when tested against Mycobacterium tuberculosis in whole-cell Reviewed by: screening assays. This is mainly due to some of the intrinsic properties of the bacilli, Pedro Almeida Silva, such as the extremely low permeability of its cell wall, slow growth, drug resistance, Fundação Universidade Federal do drug tolerance, and persistence. In this sense, understanding the pathways involved Rio Grande, Brazil Luiz Augusto Basso, in M. tuberculosis drug tolerance, persistence, and pathogenesis, may reveal new Pontifícia Universidade Católica do Rio approaches for drug development. Moreover, the need for compounds presenting a Grande do Sul, Brazil novel mode of action is of utmost importance due to the emergence of resistance not *Correspondence: Miguel Viveiros only to the currently used antituberculosis agents, but also to those in the pipeline.
    [Show full text]
  • Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
    International Journal of Molecular Sciences Review Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery Qingxin Li 1,* and CongBao Kang 2,* 1 Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Guangdong Provincial Bioengineering Institute (Guangzhou Sugarcane Industry Research Institute), Guangdong Academy of Sciences, Guangzhou 510316, China 2 Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, Chromos, #05-01, Singapore 138670, Singapore * Correspondence: [email protected] (Q.L.); [email protected] (C.K.); Tel.: +86-020-84168436 (Q.L.); +65-64070602 (C.K.) Received: 12 June 2020; Accepted: 20 July 2020; Published: 24 July 2020 Abstract: Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins. These compounds have a low molecular weight, making them penetrate cells easily. Small-molecule drugs can be developed from leads derived from rational drug design or isolated from natural resources. A target-based drug discovery project usually includes target identification, target validation, hit identification, hit to lead and lead optimization. Understanding molecular interactions between small molecules and their targets is critical in drug discovery. Although many biophysical and biochemical methods are able to elucidate molecular interactions of small molecules with their targets, structural biology is the most powerful tool to determine the mechanisms of action for both targets and the developed compounds. Herein, we reviewed the application of structural biology to investigate binding modes of orthosteric and allosteric inhibitors. It is exemplified that structural biology provides a clear view of the binding modes of protease inhibitors and phosphatase inhibitors.
    [Show full text]
  • Chemogenomics: an Emerging Strategy for Rapid Target and Drug Discovery
    REVIEWS CHEMOGENOMICS: AN EMERGING STRATEGY FOR RAPID TARGET AND DRUG DISCOVERY Markus Bredel*‡ and Edgar Jacoby§ Chemogenomics is an emerging discipline that combines the latest tools of genomics and chemistry and applies them to target and drug discovery. Its strength lies in eliminating the bottleneck that currently occurs in target identification by measuring the broad, conditional effects of chemical libraries on whole biological systems or by screening large chemical libraries quickly and efficiently against selected targets. The hope is that chemogenomics will concurrently identify and validate therapeutic targets and detect drug candidates to rapidly and effectively generate new treatments for many human diseases. Over the past five decades, pharmacological compounds however, that owing to the emergence of various sub- TRANSCRIPTIONAL PROFILING The study of the transcriptome have been identified that collectively target the products specialties of chemogenomics (discussed in the next — the complete set of RNA of ~400–500 genes in the human body; however, only section) and the involvement of several disciplines, it is transcripts that are produced by ~120 of these genes have reached the market as the tar- currently almost impossible to give a simple and com- the genome at any one time — gets of drugs1,2.The Human Genome Project3,4 has mon definition for this research discipline (BOX 1). using high-throughput methods, such as microarray made available many potential new targets for drug In chemogenomics-based drug discovery, large col- analysis. intervention: several thousand of the approximately lections of chemical products are screened for the paral- 30,000–40,000 estimated human genes4 could be associ- lel identification of biological targets and biologically ated with disease and, similarly, several thousand active compounds.
    [Show full text]
  • Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer
    pharmaceutics Review Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer Sibusiso Alven, Xhamla Nqoro , Buhle Buyana and Blessing A. Aderibigbe * Department of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa; [email protected] (S.A.); [email protected] (X.N.); [email protected] (B.B.) * Correspondence: [email protected] Received: 24 November 2019; Accepted: 30 December 2019; Published: 29 April 2020 Abstract: Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer. Keywords: breast cancer; lung cancer; chemotherapy; polymer-based carriers; polymer-drug conjugates 1. Introduction Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]. It is the second cause of death worldwide, followed by cardiovascular diseases [2]. It is characterized by an abnormal uncontrolled proliferation of any type of cells in the human body [3]. It is caused by external factors, such as smoking, infectious organisms, pollution, and radiation; it is also caused by internal factors, such as immune conditions, hormones, and genetic mutation [3].
    [Show full text]
  • Downloading Only Compounds with the Properties “Drug-Like”, “Purchasable”
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.02.433618; this version posted June 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors Enrico Glaab*†1, Ganesh Babu Manoharan2, Daniel Abankwa*2 1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 7 avenue des Hauts Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg 2Department of Life Sciences and Medicine, University of Luxembourg, 7 avenue des Hauts Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg *EG and DA are joint senior autHors †Contact: [email protected] Abstract Among the biomedical efforts in response to the current coronavirus (COVID-19) pandemic, pharmacological strategies to reduce viral load in patients with severe forms of the disease are being studied intensively. One of the main drug target proteins proposed so far is the SARS- CoV-2 viral protease 3CLpro (also called Mpro), an essential component for viral replication. Ongoing ligand- and receptor-based computational screening efforts would be facilitated by an improved understanding of the electrostatic, hydrophobic and steric features that characterize small molecule inhibitors binding stably to 3CLpro, as well as by an extended collection of known binders. Here, we present combined virtual screening, molecular dynamics simulation, machine learning and in vitro experimental validation analyses which have led to the identification of small molecule inhibitors of 3CLpro with micromolar activity, and to a pharmacophore model that describes functional chemical groups associated with the molecular recognition of ligands by the 3CLpro binding pocket.
    [Show full text]